Coliprotec F4/F18 (--) - Lyophilisate for oral suspension
Coliprotec F4/F18 (--) - Lyophilisate for oral suspension
Authorised
- Escherichia coli, serotype O8:K87 (fimbrial adhesin F4ac), Live
- Escherichia coli, serotype O141:K94 (fimbrial adhesin F18ac), Live
Product identification
Medicine name:
Coliprotec F4/F18 (--) - Lyophilisate for oral suspension
Active substance:
- Escherichia coli, serotype O8:K87 (fimbrial adhesin F4ac), Live
- Escherichia coli, serotype O141:K94 (fimbrial adhesin F18ac), Live
Target species:
-
Pig
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Escherichia coli, serotype O8:K87 (fimbrial adhesin F4ac), LivePresentation_strength:0.13-0.9 billion CFU Reference:Hse Index:0
-
Escherichia coli, serotype O141:K94 (fimbrial adhesin F18ac), LivePresentation_strength:0.28-3 billion CFU Reference:Hse Index:1
Pharmaceutical form:
-
Lyophilisate for oral suspension
Withdrawal period by route of administration:
-
Oral use
-
Pig
-
Not applicable0dayZero days
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI09AE03
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Available in:
-
Austria
-
Belgium
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Hungary
-
Ireland
-
Italy
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Slovakia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Package description:
- Packaging:Vial (glass), Package_size:4 vials, Content:11 ml (50 doses)
- Packaging:Vial (glass), Package_size:1 vial, Content:50 ml (200 doses)
- Packaging:Vial (glass), Package_size:1 vial, Content:11 ml (50 doses)
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Elanco GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Lohmann Animal Health GmbH
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 6/06/2024
Bulgarian (PDF)
Published on: 6/06/2024
Croatian (PDF)
Published on: 6/06/2024
Czech (PDF)
Published on: 6/06/2024
Danish (PDF)
Published on: 6/06/2024
Dutch (PDF)
Published on: 6/06/2024
Estonian (PDF)
Published on: 6/06/2024
Finnish (PDF)
Published on: 6/06/2024
French (PDF)
Published on: 6/06/2024
German (PDF)
Published on: 6/06/2024
Greek (PDF)
Published on: 6/06/2024
Hungarian (PDF)
Published on: 6/06/2024
Icelandic (PDF)
Published on: 6/06/2024
Italian (PDF)
Published on: 6/06/2024
Latvian (PDF)
Published on: 6/06/2024
Lithuanian (PDF)
Published on: 6/06/2024
Maltese (PDF)
Published on: 6/06/2024
Norwegian (PDF)
Published on: 6/06/2024
Polish (PDF)
Published on: 6/06/2024
Portuguese (PDF)
Published on: 6/06/2024
Romanian (PDF)
Published on: 6/06/2024
Slovak (PDF)
Published on: 6/06/2024
Slovenian (PDF)
Published on: 6/06/2024
Spanish (PDF)
Published on: 6/06/2024
Swedish (PDF)
Published on: 6/06/2024
